linjc16/ctgov huggingface dataset:
Becoming Traumatic Brain Injured Patients at Day 7 of Their Trauma

Study Overview
=================
Brief Summary
-----------------
To study the future of traumatic brain injured patients at day 7 of their trauma Primary endpoint: Fate, classified as survival with or without sequelae, death. Use of the GOS-E scale to classify survival with or without sequelae. The collection of this scale will be done by telephone contact, 7 days of admission to the emergency room. Secondary judgment criteria: Compendium of the realization of the CT / time respected between the TCL and the CT / Hospitalization / 2nd CT to realize at 24 hours in the patients treated by TAC or AAP Application of the recommendations of the French Society of Emergency Medicine 2012: Become 7 days of patients classified according to whether or not the recommendations, . Become TCL patients under AAP or TAC Number of reconsultation, rehospitalization, new imaging within 7 days after TCL

Official Title
-----------------
Becoming Traumatic Brain Injured Patients at Day 7 of Their Trauma in Poitiers Emergency

Conditions
-----------------
Traumatic Brain Injury

Intervention / Treatment
-----------------
* Other: GOS-E


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient of both sexes, at least 18 years old, Patient with mild head trauma, Glasgow 13-15 Patient without tutorship or curatorship Affiliation to social security No opposition of the patient or relatives to participation in the study. Exclusion Criteria: Patient already included in this study Refusal to participate in this search Patient undergoing enhanced protection (persons deprived of liberty by a judicial or administrative decision, adults under legal protection).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: GOS-E|Call at 7 days, patients add a brain trauma to know their sequeals|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Becoming of traumatic brain injured patients: becoming classified in alive with or without sequelae or death, by using scale of GOS E |  | 7 days |
Central Post-Stroke Pain - a Prospective Study

Study Overview
=================
Brief Summary
-----------------
Part 1: The purpose of the first part of the study is to investigate the prevalence of pain at stroke onset and 3 and 6 months after stroke in a consecutive cohort of stroke patients admitted to a stroke unit. Part 2: The purpose of the second part of the study is to identify patients who develop central post-stroke pain within the first 6 months following stroke and to try to identify early prognostic factors for the development of pain.

Detailed Description
-----------------
Part 1: Within 3 days of admission: medical history, pain history, sensory examination Telephone follow-up at 3 and 6 months post-stroke: pain history Part 2: Medical history, Pain history, Sensory examination

Official Title
-----------------
Central Post-Stroke Pain - a Prospective Study of Consecutively Admitted Patients With Recent Stroke

Conditions
-----------------
Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recent cerebrovascular stroke Exclusion Criteria: Severe dementia, aphasia or psychosis Patients who cannot cooperate at time of inclusion Patients who do not understand Danish

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Central post-stroke pain, post-stroke pain, shoulder pain
Minimal Invasiveness of Endoscopic Thyroidectomy

Study Overview
=================
Brief Summary
-----------------
The investigators had performed more than 250 cases of breast approach endoscopic thyroidectomy (BAET). The goal of this study is to evaluate whether BAET could be a minimally invasive procedure under the expert's hands.

Official Title
-----------------
Minimal Invasiveness of Endoscopic Thyroidectomy

Conditions
-----------------
Thyroid Nodule

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: thyroidectomy nodule diagnosed by ultrasound Exclusion Criteria: thyroid carcinoma
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1:endoscopic group<br>patients underwent endoscopic thyroidectomy | |
| 2:conventional group<br>patients underwent open thyroidectomy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum IL-6 and CRP levels before and after operation |  | 0, 2, 12, 24, 48 hours after surgery | 
| Visual Analogue Scale (VAS) score |  | 2, 12, 24, 48 hours after surgery | 
| Cosmetic outcomes after surgery |  | 3 months after surgery |
Whole-body MRI for the Detection of Metastasis

Study Overview
=================
Brief Summary
-----------------
Develop and optimize protocols for whole body MRI for detection of metastases. Evaluate diagnostic accuracy through application of optimized protocols for screening of cancer patients.

Official Title
-----------------
Whole-body MRI for the Detection of Metastasis

Conditions
-----------------
Breast Cancer, Metastases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Cancer patient Exclusion Criteria: Poor general condition Pacemaker or other MRI contraindications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Advanced breast cancer<br>Women with advanced breast cancer | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of metastasis in skeleton | Number of skeleton metastasis will be assessed at the regular clinical follow-up of breast cancer patients with metastatic disease | Baseline and after 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Magnetic Resonance Imaging, Data Accuracy, Reproducibility of Results, Diagnosis
B Vitamin Deficiency and Pregnancy Complications

Study Overview
=================
Brief Summary
-----------------
This case-control study aims to investigate the association between B vitamins and gestational hypertension or preeclampsia.

Detailed Description
-----------------
In clinical practice, women diagnosed with gestational hypertension or preeclampsia will be asked to participate this study to fill a questionnaire reporting their basic information. Meanwhile, women with matched age and gestation week and without any kinds of hypertensive disorders will also be invited for this study. Participants' blood samples will be analyzed for B vitamin levels at the end of the study.

Official Title
-----------------
B Vitamin Deficiency and Pregnancy Complications

Conditions
-----------------
Gestational Hypertension, Preeclampsia

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant women aged 18-40 years old Exclusion Criteria: women with Hepatitis B, syphilis, HIV/AIDS and other infectious diseases. women with severe physical or mental diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Case subjects diagnosed with gestational hypertension or preeclampsia<br>This is a restrospective observational study and there is no intervention. | Other: No intervention<br>* No intervention<br>|
| Control subjects diagnosed without any hypertensive disorders<br>This is a restrospective observational study and there is no intervention. | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| gestational hypertension | Gestational hypertension is diagnosed when blood pressure readings are higher than 140/90 mm Hg in a woman who had normal blood pressure prior to 20 weeks and has no proteinuria (excess protein in the urine). | seven days after delivery | 
| preeclampsia | Gestational hypertension is diagnosed when blood pressure readings are higher than 140/90 mm Hg in a woman who had normal blood pressure prior to 20 weeks and has positive proteinuria (excess protein in the urine). | seven days after delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
B vitamins, pregnancy complications
Efficacy of Probiotics on Physical Performance

Study Overview
=================
Brief Summary
-----------------
Efficacy of probiotics on physical performance

Official Title
-----------------
Efficacy of Probiotics on Physical Performance

Conditions
-----------------
Physical Performance

Intervention / Treatment
-----------------
* Dietary Supplement: Probiotic supplement
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female, aged 18 to 40 years, at the time of signing the informed consent form Provides signed and dated informed consent form Engaged in competitive sports and regularly training Non-anemic, iron-deficient Willing to comply with all study procedures and be available for the duration of the study Exclusion Criteria: Use of probiotics Use of iron supplementation Use of ascorbic acid (Vitamin C) supplementation Hypersensitivity to any of the ingredients in the investigational product (IP)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Probiotic supplement<br> | Dietary Supplement: Probiotic supplement<br>* Probiotic supplement<br>|
| Placebo Comparator: Placebo<br> | Dietary Supplement: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolic response at standardized workloads during ergometer cycling | Change from baseline in metabolic response at standardized workloads during ergometer cycling after 4,8 and 12 weeks of supplementation | 4,8 and 12 weeks |
Covid 19 Vaccine Acceptance in Egyptian Pregnant Women

Study Overview
=================
Brief Summary
-----------------
To determine vaccine acceptance and hesitancy attitudes toward coronavirus disease 2019 (COVID-19) vaccines in Egyptian pregnant women.

Detailed Description
-----------------
Although 2 years passed since the Covid 19 pandemic started, no specific treatment against the disease is available. According to WHO, more than two million deaths have been recorded worldwide . Therefore, it is important to avoid infection. In the absence of an effective treatment for coronavirus disease 2019 (COVID-19) non-pharmaceutical interventions are the only available methods of disease control. Social distancing, face masks, and personal hygiene are the most effective precautions, but maintaining these actions is not practicable in the long term. As a result, vaccination becomes the most effective eradication method. (1,2) Research into development of a vaccine for SARS-CoV-2 was undertaken immediately after the disease was identified.(3) The success of a vaccine depends not only on its efficacy, but also its acceptance. However, vaccine hesitancy has become an important threat to global health, which was pointed out by WHO in 2019.(4) Several key factors behind vaccine hesitancy include fear or mistrust of the vaccine, underestimation of the value of the vaccine, and lack of access to the vaccine.(5) Pregnant women are at increased risk of severe disease, ICU admission, and ventilation when compared with non-pregnant patients of the same age.(6-8) Therefore, pregnant women are classified as a high-risk population for COVID-19 infection.(9) Regarding this information, pregnant women have not been included in any COVID-19 vaccine clinical trials to date.(10) Even so, public health authorities, including the ACOG and the SMFM recommend that COVID-19 vaccines should be available for pregnant women if they prefer to be vaccinated.(11,12)

Official Title
-----------------
Covid Vaccine Acceptance Among Egyptian Pregnant Women

Conditions
-----------------
COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant women at any gestational age Exclusion Criteria: Covid 19 suspicious patients at time of survey. patients refusing survey obstetric emergency.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| acceptance of and attitude toward f COVID-19 vaccination |  | 5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the impact of the COVID-19 pandemic |  | 5 months | 
| perception of risk related to the COVID-19 pandemic |  | 5 months | 
| Improvement of vaccination status among pregnant women |  | 5 months |
Validation of Chinese Version Appropriate Use Criteria for Coronary Revascularization

Study Overview
=================
Brief Summary
-----------------
Coronary revascularization (CR) is increasing rapidly in China and varies significantly in proportion ( PCI:CABG=15:1). Few studies assess the appropriateness of CR in China. Recently, National Center for Cardiovascular Disease organized experts to release Chinese version appropriate use criteria(C-AUC) for coronary revascularization by RAND method aimed at regulating indications of CR. The criteria is considered to contribute to clinical practices, quality assessment and health insurance policy, however, the validation of C-AUC is unknown. Thus the investigators study aims at assessing the validation of Chinese AUC by multi-center prospective registry. The investigators will recruit 4000 patients undergoing elective coronary angiography with positive outcome consecutively and collect baseline information. Sequently, one-year follow up will be done to collect the prognose, including death, rehospitalization, medicine, medical compliance and life quality etc. One hand, the investigators will compare the outcomes between different therapies in the same indications according to C-AUC to evaluate the validation of C-AUC. On the other hand, the investigators will evaluate the rationality of CAD therapy in Beijing by C-AUC.

Official Title
-----------------
Validation of Chinese Version Appropriate Use Criteria for Coronary Revascularization

Conditions
-----------------
Appropriate Use Criteria, Coronary Revascularization

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergo elective coronary angiography in department of cardiology in period of study Written informed consent Exclusion Criteria: Age ≤18 years of age Illiteracy, vision/audition disorder, cognitive disorder etc

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| appropriate in appropriate indications<br> | |
| inappropriate in appropriate indications<br> | |
| appropriate in inappropriate indications<br> | |
| inappropriate in inappropriate indications<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiac and cerebrovascular events (MACCE) | death, nonfatal myocardial infarction, cerebrovascular event, repeat revascularization | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| death |  | 1 year | 
| recurrent hospitalizations for acute coronary syndrome (ACS) |  | 1 year | 
| cerebrovascular event |  | 1 year | 
| repeat revascularization |  | 1 year | 
| cost for hospitalization | Total cost of hospitalization and rehospitalization for cardiac disease in follow-up time | 1 year |
Next Generation X-ray Imaging System

Study Overview
=================
Brief Summary
-----------------
Philips Healthcare has developed a next generation Allura investigational device. The intended purpose of the investigational device is to perform neurovascular imaging applications, including diagnostic, interventional and minimally invasive procedures on human patients. The goal of this study is to investigate the accuracy of the next generation Allura investigational device to determine the extent and localization of ischemic stroke changes in brain tissue.

Official Title
-----------------
Next Generation X-ray Imaging System

Conditions
-----------------
Stroke, Acute

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient has signed and dated the Informed Consent Form (ICF) Age ≥ 50 years old Clinical and radiological signs consistent with acute stroke I. Patient diagnosed with ischemic stroke of the anterior circulation and not eligible for thrombectomy. II. Patient diagnosed with ischemic stroke of the anterior circulation and subjected to thrombectomy. III. Patient diagnosed with hemorrhagic stroke. Exclusion Criteria: Pregnant or breastfeeding women. Previous stroke or parenchymal damage/defects in anterior circulation territories (only applicable for subjects included by criterion 3.I or 3.II). Subject participates in a potentially confounding drug or device trial during the course of the study. Participation in the study exposes the subject to risk, as assessed at the discretion of the treating physician. All subjects who meet an exclusion criteria according to national law. Subject or subject family member is a known Philips employee.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ischemic stroke diagnostic accuracy | Accuracy of ASPECTS score to determine the extent and localization of ischemic stroke changes in brain tissue, evaluated by three independent neuroradiologists. | Within 2 days after procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vessel tree visibility | Proportion of images made with new investigational device rated non-inferior vessel visibility compared to CTA (reference standard) | Within 2 days after procedure | 
| Intracranial hemorrhage detection accuracy | Accuracy of images made with new investigational device to determine the presence of intracranial hemorrhage using neCT as the reference standard | Within 2 days after procedure |
Association Between Mitochondrial DNA Content and Risk of Coronary Heart Disease

Study Overview
=================
Brief Summary
-----------------
Compelling epidemiological evidence indicates that alterations of mitochondrial DNA, including mutations and abnormal content of mitochondrial DNA (mtDNA), are associated with the initiation and development of cardiovascular disease. This study was undertaken to investigate whether mtDNA copy number in peripheral blood cells could be used as a risk predictor for coronary heart disease.

Official Title
-----------------
Association Between Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Coronary Heart Disease

Conditions
-----------------
Coronary Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of documented myocardial infarction; Prior coronary revascularization intervention (coronary artery bypass graft surgery or percutaneous coronary intervention); The presence of ≥ 50% stenosis in one or more coronary arteries identified during cardiac catheterization; Exclusion Criteria: History of malignancy or end-stage renal disease; Blood transfusion within one month or prior bone marrow transplantation Patients who reluctant to sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CHD group<br>200 consecutive patients were recruited, who have diagnosed with coronary heart disease(CHD) by coronary angiography. | |
| Control group<br>The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relative copy number of mitochondrial DNA | The ratio of mitochondrial DNA copy number to hemoglobin copy number was calculated for each sample from standard curves. After that, the ratio for each sample was normalized to a calibrator DNA in order to standardize between different runs, and then defined as the measurement of relative mtDNA copy number.Relative copy number of Mitochondrial DNA were measured in CHD patients in comparison to control group. | From date of percutaneous coronary intervention until the date of discharging from hospital, assessed up to 5 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mitochondrial DNA copy number, Peripheral blood cells